Summit Therapeutics (NASDAQ:SMMT - Get Free Report) had its price target decreased by equities research analysts at Citigroup from $43.00 to $42.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Citigroup's price target suggests a potential upside of 252.53% from the stock's previous close.
Several other brokerages also recently weighed in on SMMT. Guggenheim reaffirmed a "buy" rating on shares of Summit Therapeutics in a research note on Wednesday, August 26th. Stifel Nicolaus dropped their price objective on shares of Summit Therapeutics from $45.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, July 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Summit Therapeutics in a research report on Thursday, October 15th. Barclays decreased their price target on Summit Therapeutics from $20.00 to $18.00 and set an "equal weight" rating on the stock in a research note on Monday. Finally, UBS Group restated a "neutral" rating on shares of Summit Therapeutics in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $28.38.
Read Our Latest Research Report on SMMT
Summit Therapeutics Stock Performance
Shares of SMMT traded down $2.24 during trading hours on Monday, hitting $11.91. The stock had a trading volume of 17,177,827 shares, compared to its average volume of 4,702,207. The firm has a market capitalization of $9.53 billion, a price-to-earnings ratio of -11.07 and a beta of -1.49. The firm has a 50-day moving average price of $16.41 and a 200 day moving average price of $16.14. Summit Therapeutics has a fifty-two week low of $11.69 and a fifty-two week high of $29.23.
Hedge Funds Weigh In On Summit Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers raised its position in shares of Summit Therapeutics by 54.3% during the third quarter. Cetera Investment Advisers now owns 44,592 shares of the company's stock worth $754,000 after purchasing an additional 15,691 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Summit Therapeutics by 1.1% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company's stock worth $1,611,000 after purchasing an additional 1,025 shares in the last quarter. Xcelsior Advisor Partners LLC lifted its stake in Summit Therapeutics by 199.7% during the third quarter. Xcelsior Advisor Partners LLC now owns 53,874 shares of the company's stock valued at $911,000 after buying an additional 35,899 shares in the last quarter. Ieq Capital LLC acquired a new position in shares of Summit Therapeutics in the third quarter worth about $1,179,000. Finally, Z3 Capital Partners LLC purchased a new position in shares of Summit Therapeutics in the third quarter worth approximately $618,000. 4.61% of the stock is owned by institutional investors.
Trending Headlines about Summit Therapeutics
Here are a few of the latest headlines about SMMT:
- Neutral Sentiment: Options trading was unusually active: traders acquired 49,767 call options, about 424% above the average daily volume. That signals heightened interest, but does not by itself establish a bullish outlook. 2 Cancer-Drug Developers Seeing Unusual Options Volume
- Negative Sentiment: The FDA issued a Complete Response Letter for ivonescimab with platinum-containing chemotherapy in previously treated, locally advanced or metastatic non-small cell lung cancer. The drug cannot be approved on the current application, delaying its potential U.S. launch; the supplied reports do not specify the FDA’s reasons. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Negative Sentiment: Barclays cut its price target from $20 to $18 while maintaining an “equal weight” rating, adding to the cautious tone around the stock. Barclays Stock Recommendations
Summit Therapeutics Company Profile
(
Get Free Report)
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit's licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.